PT - JOURNAL ARTICLE AU - Jonathon W. Senefeld AU - Patrick W. Johnson AU - Katie L. Kunze AU - Noud van Helmond AU - Stephen A. Klassen AU - Chad C. Wiggins AU - Katelyn A. Bruno AU - Michael A. Golafshar AU - Molly M. Petersen AU - Matthew R. Buras AU - Allan M. Klompas AU - Matthew A. Sexton AU - Juan C. Diaz Soto AU - Sarah E. Baker AU - John R.A. Shepherd AU - Nicole C. Verdun AU - Peter Marks AU - Camille M. van Buskirk AU - Jeffrey L. Winters AU - James R. Stubbs AU - Robert F. Rea AU - Vitaly Herasevich AU - Emily R. Whelan AU - Andrew J. Clayburn AU - Kathryn F. Larson AU - Juan G. Ripoll AU - Kylie J. Andersen AU - Matthew N.P. Vogt AU - Joshua J. Dennis AU - Riley J. Regimbal AU - Philippe R. Bauer AU - Janis E. Blair AU - Katherine Wright AU - Joel T. Greenshields AU - Nigel S. Paneth AU - DeLisa Fairweather AU - R. Scott Wright AU - Arturo Casadevall AU - Rickey E. Carter AU - Michael J. Joyner TI - Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma AID - 10.1101/2021.04.08.21255115 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.08.21255115 4099 - http://medrxiv.org/content/early/2021/04/11/2021.04.08.21255115.short 4100 - http://medrxiv.org/content/early/2021/04/11/2021.04.08.21255115.full AB - Background The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents particularly for vulnerable racial and ethnic minority populations who were disproportionately affected by the pandemic. The objective of this study is to report on the demographic, geographic, and chronological access to COVID-19 convalescent plasma in the US via the EAP.Methods and findings Mayo Clinic served as the central IRB for all participating facilities and any US physician could participate as local physician–principal investigator. Registration occurred through the EAP central website. Blood banks rapidly developed logistics to provide convalescent plasma to hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal trends in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate on a state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions as well as assessing enrollment in metropolitan and less populated areas which did not have access to COVID-19 clinical trials.From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP. A majority of patients were older than 60 years of age (57.8%), male (58.4%), and overweight or obese (83.8%). There was substantial inclusion of minorities and underserved populations, including 46.4% of patients with a race other than White, and 37.2% of patients were of Hispanic ethnicity. Severe or life-threatening COVID-19 was present in 61.8% of patients and 18.9% of patients were mechanically ventilated at time of convalescent plasma infusion. Chronologically and geographically, increases in enrollment in the EAP closely followed confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled patients in the EAP, including both in metropolitan and less populated areas.Conclusions The EAP successfully provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The efficient study design of the EAP may serve as an example framework for future efforts when broad access to a treatment is needed in response to a dynamic disease affecting demographic groups and areas historically underrepresented in clinical studies.Competing Interest StatementUnited Health Group, Millennium Pharmaceuticals, and Octapharma USA Inc., supported this project. No other disclosures were reported.Clinical TrialNCT04338360Funding StatementThis project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. Additionally, this study was supported in part by National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ) and grant 1F32HL154320 (to JWS), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CCW), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 AI154927 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute RO1 HL059842 (to AC), National Institute on Aging (NIA) U54AG044170 (to SEB), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc, and the Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mayo Clinic Institutional Review Board (IRB), the central IRB for the registry, approved the protocol (IRB #20-0033412, NCT#: NCT04338360), all amendments, and provided regulatory oversight for all sites and investigators. The principal investigator (M.J.J.) was the regulatory sponsor. A Data and Safety Monitoring Board oversaw the safety analyses and advised the regulatory sponsor and the Mayo Clinic IRB on risk.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data underlying the results reported in this publication, along with a data dictionary, will be made available to approved investigators for secondary analyses following the completion of the objectives of the United States Expanded Access Program to COVID-19 convalescent plasma. Limited and de-identified data sets will be deposited into a research data repository and may be shared with investigators under controlled access procedures as approved by the Mayo Clinic Institutional Review Board. A scientific committee will review requests for the conduct of protocols approved or determined to be exempt by an Institutional Review Board. Requestors will be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies.